In the last trading session, 2.08 million shares of the Xeris Biopharma Holdings Inc (NASDAQ:XERS) were traded, and its beta was 0.99. Most recently the company’s share price was $4.16, and it changed around $0.0 or 0.00% from the last close, which brings the market valuation of the company to $640.39M. XERS currently trades at a discount to its 52-week high of $6.07, offering almost -45.91% off that amount. The share price’s 52-week low was $1.69, which indicates that the current value has risen by an impressive 59.38% since then. We note from Xeris Biopharma Holdings Inc’s average daily trading volume that its 10-day average is 3.75 million shares, with the 3-month average coming to 2.89 million.
Xeris Biopharma Holdings Inc stock received a consensus recommendation rating of Buy, based on a mean score of 1.33. If we narrow it down even further, the data shows that 0 out of 6 analysts rate the stock as a Sell; another 1 rate it as Overweight. Among the rest, 1 recommended XERS as a Hold, whereas 4 deemed it a Buy, and 0 rated it as Underweight. Xeris Biopharma Holdings Inc is expected to report earnings per share of -0.04 for the current quarter.
Xeris Biopharma Holdings Inc (NASDAQ:XERS) trade information
The performance over the last five days has remained in the red territory. The rise to weekly highs of 4.65 on recent trading dayincreased the stock’s daily price by 10.54%. The company’s shares are currently up 22.71% year-to-date, but still down -5.67% over the last five days. On the other hand, Xeris Biopharma Holdings Inc (NASDAQ:XERS) is -13.69% down in the 30-day period. We can see from the shorts that 17.04 million shares have been sold at a short interest cover period of 4.02 day(s).
The consensus price target as assigned by Wall Street analysts is $5, which translates to bulls needing to increase their stock price by 16.8% from its current value. Analyst projections state that XERS is forecast to be at a low of $4 and a high of $6.6.
Xeris Biopharma Holdings Inc (XERS) estimates and forecasts
The year-over-year growth rate is expected to be 29.17%, up from the previous year.
Consensus estimates provided by 6 financial analysts predict the company will bring in an average of 57.61M in revenue for the current quarter. 6 analysts expect Xeris Biopharma Holdings Inc to make 62.65M in revenue for the current ending quarter. The company’s sales for the same quarters a year ago were 40.64M and 48.06M respectively. Analysts predict that the company’s current quarter sales will jump, forecast at 41.76%. Forecasts for the next quarter put sales growth at 30.35%.
Looking at the company’s year-over-year earnings, the past five years showed a positive earnings growth rate of 40.01%.
XERS Dividends
Xeris Biopharma Holdings Inc’s next quarterly earnings report is expected to be released on 2025-Mar-05.
Xeris Biopharma Holdings Inc (NASDAQ:XERS)’s Major holders
Upon looking at major shareholders, it appears that insiders hold 4.09% of Xeris Biopharma Holdings Inc shares, and 42.86% of them are in the hands of institutional investors. The stock currently has a share float of 44.69%. Xeris Biopharma Holdings Inc stock is held by 204.0 institutions, with BLACKROCK INC. being the largest institutional investor. By 2024-06-30, it held 6.9649% of the shares, which is about 10.33 million shares worth $23.25 million.
VANGUARD GROUP INC, with 5.4492% or 7.66 million shares worth $17.23 million as of 2024-06-30, holds the second largest percentage of outstanding shares.
VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund and iShares Trust-iShares Russell 2000 ETF were the top two Mutual Funds as of Dec 31, 2024 . The former held 4.22 shares worth $17.56 million, making up 2.74% of all outstanding shares. On the other hand, iShares Trust-iShares Russell 2000 ETF held roughly 3.58 shares worth around $14.9 million, which represents about 2.33% of the total shares outstanding.
